Should I buy or sell Intra-Cellular Therapies stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ITCI shares. View ITCI analyst ratings or view top-rated stocks .

What is Intra-Cellular Therapies' stock price target for 2024?

8 brokerages have issued 1-year target prices for Intra-Cellular Therapies' stock. Their ITCI share price targets range from $62.00 to $101.00. On average, they anticipate the company's share price to reach $78.67 in the next year. This suggests a possible upside of 32.4% from the stock's current price. View analysts price targets for ITCI or view top-rated stocks among Wall Street analysts .

How have ITCI shares performed in 2023?

Intra-Cellular Therapies' stock was trading at $52.92 at the beginning of 2023. Since then, ITCI stock has increased by 12.3% and is now trading at $59.43. View the best growth stocks for 2023 here .

Are investors shorting Intra-Cellular Therapies?

Intra-Cellular Therapies saw a increase in short interest in November. As of November 15th, there was short interest totaling 3,410,000 shares, an increase of 7.9% from the October 31st total of 3,160,000 shares. Based on an average trading volume of 833,200 shares, the days-to-cover ratio is currently 4.1 days. View Intra-Cellular Therapies' Short Interest .

When is Intra-Cellular Therapies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024. View our ITCI earnings forecast .

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) issued its earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.34. The biopharmaceutical company earned $126.17 million during the quarter, compared to the consensus estimate of $118.35 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 24.91% and a negative net margin of 36.92%.

What ETFs hold Intra-Cellular Therapies' stock?

ETFs with the largest weight of Intra-Cellular Therapies (NASDAQ:ITCI) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL) , iShares Neuroscience and Healthcare ETF (IBRN) , SPDR S&P Pharmaceuticals ETF (XPH) , Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) , iShares U.S. Pharmaceuticals ETF (IHE) , Virtus LifeSci Biotech Products ETF (BBP) , Principal Healthcare Innovators ETF (BTEC) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH) .

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE) , Amarin (AMRN) , Gilead Sciences (GILD) , CRISPR Therapeutics (CRSP) , Synergy Pharmaceuticals (SGYP) , Myovant Sciences (MYOV) , Novavax (NVAX) , Pfizer (PFE) , AbbVie (ABBV) and Clovis Oncology (CLVS) .

Who are Intra-Cellular Therapies' major shareholders?

Intra-Cellular Therapies' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (11.41%), JPMorgan Chase & Co. (2.14%), Invesco Ltd. (2.01%), Clearbridge Investments LLC (1.46%), Polar Capital Holdings Plc (1.04%) and Charles Schwab Investment Management Inc. (1.02%). Insiders that own company stock include Christopher D Alafi, Christopher D Alafi , Joel S Marcus , Lawrence J Hineline, Lawrence J Hineline , Mark Neumann , Michael Halstead , Nostrand Robert L Van , Rory B Riggs , Sharon Mates and Suresh K Durgam . View institutional ownership trends .

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Intra-Cellular Therapies Stock Price, News & Analysis (NASDAQ:ITCI)

$59.43

+0.36 (+0.61%)

(As of 04:00 PM ET)

Compare

Today's Range: $58.78
▼
$60.54
50-Day Range: $46.37
▼
$59.60
52-Week Range: $42.01
▼
$67.05

Volume: 753,527 shs
Average Volume: 767,032 shs
Market Capitalization: $5.72 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $78.67

Intra-Cellular Therapies MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 32.4% Upside
$78.67 Price Target
Short Interest: Bearish
3.54% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.23
Upright™ Environmental Score
News Sentiment: 0.55
Based on 5 Articles This Week
Insider Trading: Selling Shares
$5.35 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.68) to ($0.80) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

232nd out of 949 stocks

Pharmaceutical Preparations Industry

97th out of 437 stocks

3.5

Analyst's Opinion

Consensus Rating
Intra-Cellular Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $78.67, Intra-Cellular Therapies has a forecasted upside of 32.4% from its current price of $59.43.
Amount of Analyst Coverage
Intra-Cellular Therapies has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.54% of the outstanding shares of Intra-Cellular Therapies have been sold short.
Short Interest Ratio / Days to Cover
Intra-Cellular Therapies has a short interest ratio ("days to cover") of 4.1.
Change versus previous month
Short interest in Intra-Cellular Therapies has recently increased by 7.91%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Intra-Cellular Therapies does not currently pay a dividend.
Dividend Growth
Intra-Cellular Therapies does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Intra-Cellular Therapies has received a 69.69% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is mostly driven by its "Antipsychotics", "Clinical research services for mood disorders", and "Clinical research services for substance abuse disorders " products. See details.
Environmental Sustainability
The Environmental Impact score for Intra-Cellular Therapies is -1.23.

3.1

News and Social Media Coverage

News Sentiment
Intra-Cellular Therapies has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Intra-Cellular Therapies this week, compared to 3 articles on an average week.
Search Interest
2 people have searched for ITCI on MarketBeat in the last 30 days.
MarketBeat Follows
3 people have added Intra-Cellular Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Intra-Cellular Therapies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,346,680.00 in company stock.
Percentage Held by Insiders
Only 3.40% of the stock of Intra-Cellular Therapies is held by insiders.
Percentage Held by Institutions
86.94% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($1.68) to ($0.80) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Intra-Cellular Therapies is -36.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Intra-Cellular Therapies is -36.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Intra-Cellular Therapies has a P/B Ratio of 9.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Intra-Cellular Therapies Stock (NASDAQ:ITCI)

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, heart failure, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

ITCI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ITCI Stock News Headlines

November 25, 2023 | americanbankingnews.com

Investors Purchase Large Volume of Call Options on Intra-Cellular Therapies (NASDAQ:ITCI)

November 23, 2023 | finance.yahoo.com

Wall Street Analysts Think Intra-Cellular (ITCI) Could Surge 33.02%: Read This Before Placing a Bet

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 20, 2023 | seekingalpha.com

The Right Play On Intra-Cellular Therapies

November 15, 2023 | finance.yahoo.com

Intra-Cellular Therapies to Present at the 6th Annual Evercore ISI HealthCONx Conference

November 15, 2023 | finance.yahoo.com

Insider Sell Alert: EVP Michael Halstead Sells 50,000 Shares of Intra-Cellular Therapies Inc (ITCI)

November 13, 2023 | seekingalpha.com

Intra-Cellular's Caplyta Is Well On Its Way To Being A Mental Health Blockbuster

November 7, 2023 | finance.yahoo.com

Wall Street Analysts Believe Intra-Cellular (ITCI) Could Rally 41.19%: Here's is How to Trade

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 6, 2023 | finance.yahoo.com

We Think Intra-Cellular Therapies (NASDAQ:ITCI) Can Easily Afford To Drive Business Growth

November 2, 2023 | finance.yahoo.com

Intra-Cellular Therapies Inc (ITCI) Reports Q3 2023 Earnings, Raises Sales Guidance

November 2, 2023 | finanznachrichten.de

Intra-Cellular Therapies Inc.: Intra-Cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance

November 2, 2023 | finance.yahoo.com

Intra-Cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance

October 31, 2023 | finance.yahoo.com

Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences

October 29, 2023 | finance.yahoo.com

I'm Targeting Intra-Cellular Therapies for a Covered-Call Play

October 26, 2023 | finance.yahoo.com

Intra-Cellular Therapies (ITCI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

October 26, 2023 | finance.yahoo.com

Intra-Cellular Therapies to Host Third Quarter 2023 Financial Results Conference Call and Webcast

September 20, 2023 | finance.yahoo.com

Intra-Cellular Therapies to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

September 20, 2023 | gurufocus.com

Insider Sell: Sharon Mates Sells 100,000 Shares of Intra-Cellular Therapies Inc

September 11, 2023 | benzinga.com

Intra-Cellular Therapies Announces Presentations at Psych Congress 2023 Including Positive Results from Study 403 in Mixed Features

September 5, 2023 | finance.yahoo.com

Loss-Making Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Expected To Breakeven In The Medium-Term

September 5, 2023 | finance.yahoo.com

Intra-Cellular Therapies to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

August 23, 2023 | msn.com

Cantor Fitzgerald Reiterates Intra-Cellular Therapies (ITCI) Overweight Recommendation

August 12, 2023 | seekingalpha.com

Intra-Cellular Therapies: Caplyta's Rise And A Promising Pipeline

August 4, 2023 | finance.yahoo.com

Intra-Cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance

August 3, 2023 | seekingalpha.com

Intra-Cellular Therapies Q2 2023 Earnings Preview

July 28, 2023 | finance.yahoo.com

Intra-Cellular Therapies to Host Second Quarter 2023 Financial Results Conference Call and Webcast

See More Headlines

Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2023
Today: 11/29/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/06/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ITCI
CUSIP: N/A
CIK: 1567514
Web: www.intracellulartherapies.com
Phone: (464) 440-9333
Fax: 646-440-9334
Employees: 561
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $78.67
High Stock Price Target: $101.00
Low Stock Price Target: $62.00
Potential Upside/Downside: +33.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.61)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-256,260,000.00
Net Margins: -36.92%
Pretax Margin: -36.88%
Return on Equity: -24.91%
Return on Assets: -21.34%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.81
Quick Ratio: 6.40

Sales & Book Value

Annual Sales: $250.31 million
Price / Sales: 22.71
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.93 per share
Price / Book: 8.52

Miscellaneous

Outstanding Shares: 96,240,000
Free Float: 92,966,000
Market Cap: $5.68 billion
Optionable: Optionable
Beta: 1.04

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Dr. Sharon Mates Ph.D. (Age 70)
Co-Founder, Chairman, CEO & President
Comp: $2.23M
Mr. Lawrence J. Hineline CPA (Age 67)
Senior VP of Finance, CFO, Treasurer & Assistant Secretary
Comp: $820.53k
Mr. Michael I. Halstead J.D. (Age 50)
Executive VP, General Counsel & Secretary
Comp: $983.65k
Dr. Suresh K. Durgam M.D. (Age 54)
Executive VP & Chief Medical Officer
Comp: $961.84k
Mr. Mark Neumann (Age 60)
EVP & Chief Commercial Officer
Comp: $998.36k
Dr. Robert E. Davis Ph.D. (Age 72)
Senior VP & Chief Scientific Officer
Comp: $646.12k
Mr. Juan Fernando Sanchez (Age 52)
Vice President of Corporate Communications & Investor Relations
Comp: $296.75k
Ms. Karen Patruno Sheehy Esq. (Age 61)
Senior VP & Chief Compliance Officer
Dr. Michael Olchaskey
Senior VP & Head of Regulatory Affairs
Mr. John A. Bardi
Senior VP of Market Access, Policy & Government Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ITCI Stock Analysis - Frequently Asked Questions

Should I buy or sell Intra-Cellular Therapies stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ITCI shares.
View ITCI analyst ratings or view top-rated stocks.
What is Intra-Cellular Therapies' stock price target for 2024?: 8 brokerages have issued 1-year target prices for Intra-Cellular Therapies' stock. Their ITCI share price targets range from $62.00 to $101.00. On average, they anticipate the company's share price to reach $78.67 in the next year. This suggests a possible upside of 32.4% from the stock's current price.
View analysts price targets for ITCI or view top-rated stocks among Wall Street analysts.
How have ITCI shares performed in 2023?: Intra-Cellular Therapies' stock was trading at $52.92 at the beginning of 2023. Since then, ITCI stock has increased by 12.3% and is now trading at $59.43.
View the best growth stocks for 2023 here.
Are investors shorting Intra-Cellular Therapies?: Intra-Cellular Therapies saw a increase in short interest in November. As of November 15th, there was short interest totaling 3,410,000 shares, an increase of 7.9% from the October 31st total of 3,160,000 shares. Based on an average trading volume of 833,200 shares, the days-to-cover ratio is currently 4.1 days.
View Intra-Cellular Therapies' Short Interest.
When is Intra-Cellular Therapies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our ITCI earnings forecast.
How were Intra-Cellular Therapies' earnings last quarter?: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) issued its earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.34. The biopharmaceutical company earned $126.17 million during the quarter, compared to the consensus estimate of $118.35 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 24.91% and a negative net margin of 36.92%.

What ETFs hold Intra-Cellular Therapies' stock?: ETFs with the largest weight of Intra-Cellular Therapies (NASDAQ:ITCI) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), iShares U.S. Pharmaceuticals ETF (IHE), Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH).
What other stocks do shareholders of Intra-Cellular Therapies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).
Who are Intra-Cellular Therapies' major shareholders?: Intra-Cellular Therapies' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (11.41%), JPMorgan Chase & Co. (2.14%), Invesco Ltd. (2.01%), Clearbridge Investments LLC (1.46%), Polar Capital Holdings Plc (1.04%) and Charles Schwab Investment Management Inc. (1.02%). Insiders that own company stock include Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates and Suresh K Durgam.
View institutional ownership trends.
How do I buy shares of Intra-Cellular Therapies?: Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ITCI) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial